< Go to adacap.com| This site is for health care professionals only.

Prostate Cancer

  • Disease Education
  • MOA Resources
  • Clinical Trials

Chapter 1: Why Is Precision Medicine Complicated in Advanced Prostate Cancer?

Ulka Vaishampayan, MBBS, FAB

Chapter 2: How Can Phenotypic Biomarkers Increase the Use of Precision Medicine in Advanced Prostate Cancer?

A. Oliver Sartor, MD

Chapter 3: How Does PSMA Provide a Tailored Approach in Advanced Prostate Cancer?

Neal Shore, MD, FACS

PSMA Downloadable Monograph

This monograph offers a detailed review of the possible role of phenotypic precision medicine in advanced prostate cancer.

View Monograph

PSMA Disease State Deck

This slide deck provides a visual narrative of the possible role of phenotypic precision medicine in advanced prostate cancer.

View Deck

PSMA Flash Card

The front-and-back flash card displays a quick snapshot of the key points on how phenotypic biomarkers can simplify the approach to precision medicine in advanced prostate cancer.

View Flash card
PSMA Expression infographic

Expression of PSMA on Prostate Tumor Cells

Infographic depicting the potential utility of prostate-specific membrane antigen (PSMA) for targeted radioligand imaging and therapy.

View Infographic

PSMA Expression and Relevance in Advanced Prostate Cancer

Prostate-specific membrane antigen (PSMA), a biomarker highly expressed on prostate cancer cells, is a potential target under investigation for diagnostic imaging and potential therapy.

Click Here to Learn More About PSMA and Phenotypic Precision Medicine

[177Lu]Lu-PSMA-617 Mechanism of Action

Explore the mechanism of action of targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 (177Lu-PSMA-617).

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.

Reimagining Prostate Cancer With Targeted Radioligands

Explore Clinical Trials

PSMAfore

PSMA-Targeted Therapy

A Phase III, open-label, multicenter, randomized study comparing [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) vs a change of androgen receptor-directed therapy in the treatment of taxane-naïve men with progressive metastatic castrate-resistant prostate cancer

PSMAddition

PSMA-Targeted Therapy

An open-label, randomized, Phase III study comparing [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in combination with standard of care, vs standard of care alone, in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC)

NeoRay

GRPR-Targeted Therapy

A Phase I/IIa, open-label, multicenter study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry, and antitumor activity of [177Lu]Lu-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Explore Compounds

[177Lu]Lu-PSMA-617

 

PSMA-targeted radioligand therapy being explored for the potential treatment of advanced prostate cancer

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.

Explore Pipeline Explore Clinical Trials